The US bioeconomy (biotechnology-based economic activity) currently contributes 5.1 percent or more of US GDP and has tremendous growth potential. Realizing that potential requires, among other efforts, investment by the government to advance innovation infrastructure including regulatory frameworks that are open to new technologies and don’t obstruct them.